Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer.

Front Pharmacol · 2020 · PMC7870786 · PMID 33574757

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

In scenario B, the olaparib treatment strategy gained a positive trend of gaining INHB in all the subgroups except the BRCA1, ATM, CDK12, CHEK2, PPP2R2A and RAD54 L gene alterations ( Figure 4B ).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.